drugset
drugset / Trial / NCT05907291

Evaluate the Safety, Efficacy, and Pharmacokinetics of CRN04894 in Participants With Congenital Adrenal Hyperplasia (TouCAHn)

NCT05907291 ↗

Phase 2 Completed 38 enrolled Crinetics Pharmaceuticals Inc.
NaSequentialOpen-labelTreatment

Summary

The purpose of this Phase 2, open-label, sequential dose cohort study is to evaluate the safety, efficacy, and pharmacokinetics (PK) of atumelnant (CRN04894) in participants with classic congenital adrenal hyperplasia (CAH) caused by 21-hydroxylase deficiency.

Timeline

Start
2023-07-03
Primary completion
2025-08-22
Completion
2025-08-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Atumelnant Small molecule — Oral

Indications

classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency